Accounting for patient heterogeneity in phase II clinical trials.
Phase II clinical trials typically are single-arm studies conducted to decide whether an experimental treatment is sufficiently promising, relative to standard treatment, to warrant further investigation. Many methods exist for conducting phase II trials under the assumption that patients are homogeneous. In the presence of patient heterogeneity, however, these designs are likely to draw incorrect conclusions. We propose a class of model-based Bayesian designs for single-arm phase II trials with a binary or time-to-event outcome and two or more prognostic subgroups. The designs' early stopping rules are subgroup specific and allow the possibility of terminating some subgroups while continuing others, thus providing superior results when compared with designs that ignore treatment-subgroup interactions. Because our formulation requires informative priors on standard treatment parameters and subgroup main effects, and non-informative priors on experimental treatment parameters and treatment-subgroup interactions, we provide an algorithm for computing prior hyperparameter values. A simulation study is presented and the method is illustrated by a chemotherapy trial in acute leukemia.
Wathen
J Kyle
JK
Department of Biostatistics, University of Texas, M.D. Anderson Cancer Center, Box 447, 1515 Holcombe Boulevard, Houston, TX 77030, USA. jkwathen@mdanderson.org
Thall
Peter F
PF
Cook
John D
JD
Estey
Elihu H
EH
D000465:Algorithms; D001499:Bayes Theorem; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D016013:Likelihood Functions; D011379:Prognosis; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards*